Guide for Pharmaceutical Manufacturing Industry Research & Development Medical Pharmacy Students FDA updates Guidelines
Custom Search

Monday, September 1, 2014

Antibodies successfully inhibit further infection of HIV

Broadly neutralizing antibodies against HIV successfully inhibit further infection of HIV.

A life saving treatment against HIV infection is not a dream now; it could be reality tomorrow, as researchers from National Institute of Allergy and Infectious Diseases (NIAID) USA have developed antibodies which are successful in inhibiting HIV from infecting new human CD4 cells.

Broadly neutralizing antibodies (bNAbs) are group of antibodies PGT121, VRC01 and VRC03.
These antibodies were administered to HIV patients who have discontinued drug therapy for various reasons including side effects of prolonged use and were found to keep viral load under control.

In an experimental model these antibodies (bNAbs) prevented HIV from infecting new CD4 cells derived from HIV negative donors in an invitro experimental model. These antibodies can be used in treating individuals who stop taking antiretroviral drugs, bNAbs can reduce the load of antiretroviral drugs and their side effects when combined with drug therapy.

No comments:

Like This Website on Facebook and Stay Connected Share This Article with your Friends

Latest Pharma Update

USFDA approves first drug Inmazeb to treat Ebola Virus Infection

US FDA approved first drug to treat Ebola Virus Infection (zaire ebolavirus) . So far there was no drug treatment available for Ebola virus ...

You May Also Like

If you are looking for latest Pharmaceutical Manufacturing Guidelines of USFDA, UKMHRA, TGA WHO GMP then this website is one of most popular source.
Subscribe to this website by providing your email

Enter your email address get latest Pharma Guideline and technology update by email whenever this website is updated